Last reviewed · How we verify

NCT07061925

To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

Completed Phase 2 Last updated 24 December 2025
What this trial tests

Phase 2 trial testing ALC-2203-1 in Acute Bronchitis in 169 participants. Completed in 26 November 2025.

Timeline
23 April 2025
Primary endpoint
21 November 2025
26 November 2025

Quick facts

Lead sponsorKorea Arlico Pharm. Co., Ltd
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment169
Start date23 April 2025
Primary completion21 November 2025
Estimated completion26 November 2025
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Korea Arlico Pharm. Co., Ltd — full company profile →

Who can join

19 and older, any sex, with Acute Bronchitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients with Acute Bronchitis

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Bronchitis

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07061925.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing